240 related articles for article (PubMed ID: 26012207)
1. MMP inhibitors and cancer treatment trials, limitations and hopes for the future.
Tlatli R; El Ayeb M
Arch Inst Pasteur Tunis; 2013; 90(1-4):3-21. PubMed ID: 26012207
[TBL] [Abstract][Full Text] [Related]
2. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
3. New approaches to selectively target cancer-associated matrix metalloproteinase activity.
Tauro M; McGuire J; Lynch CC
Cancer Metastasis Rev; 2014 Dec; 33(4):1043-57. PubMed ID: 25325988
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.
Folgueras AR; Pendás AM; Sánchez LM; López-Otín C
Int J Dev Biol; 2004; 48(5-6):411-24. PubMed ID: 15349816
[TBL] [Abstract][Full Text] [Related]
5. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
Winer A; Adams S; Mignatti P
Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
[TBL] [Abstract][Full Text] [Related]
6. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
7. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase enzymes and their naturally derived inhibitors: novel targets in photocarcinoma therapy.
Gupta A; Kaur CD; Jangdey M; Saraf S
Ageing Res Rev; 2014 Jan; 13():65-74. PubMed ID: 24355347
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
Pavlaki M; Zucker S
Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
[TBL] [Abstract][Full Text] [Related]
10. Seesaw of matrix metalloproteinases (MMPs).
Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
[TBL] [Abstract][Full Text] [Related]
11. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
13. An updated patent therapeutic agents targeting MMPs.
Shi ZG; Li JP; Shi LL; Li X
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):74-101. PubMed ID: 21854361
[TBL] [Abstract][Full Text] [Related]
14. The other side of MMPs: protective roles in tumor progression.
Martin MD; Matrisian LM
Cancer Metastasis Rev; 2007 Dec; 26(3-4):717-24. PubMed ID: 17717634
[TBL] [Abstract][Full Text] [Related]
15. Progress in the development of matrix metalloproteinase inhibitors.
Tu G; Xu W; Huang H; Li S
Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
[TBL] [Abstract][Full Text] [Related]
16. Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
Alcantara MB; Dass CR
J Pharm Pharmacol; 2014 Jul; 66(7):895-902. PubMed ID: 24697787
[TBL] [Abstract][Full Text] [Related]
17. The past, present and future perspectives of matrix metalloproteinase inhibitors.
Li K; Tay FR; Yiu CKY
Pharmacol Ther; 2020 Mar; 207():107465. PubMed ID: 31863819
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
19. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
Gialeli C; Theocharis AD; Karamanos NK
FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
Chaudhary AK; Pandya S; Ghosh K; Nadkarni A
Mutat Res; 2013; 753(1):7-23. PubMed ID: 23370482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
